

For all patients

Pain management, psychological management, weight loss, smoking cessation

Hurley I



< 4 flares / year

≥ 4 flares / year

During flares

- Clavulanic acid amoxicillin
50 mg/kg/d (1g 3/d;
maximum 4.5 g)
OR
- Pristinamycin (1g 3/d)
For 7 days

Preventive treatment

- Cyclines (doxycycline 100
mg/d*** or lymecycline 300
mg/d)
OR
- Co-trimoxazole* 400/80
1/d***
Re-evaluation at 6 months

During flares

Add the proposed antibiotic
therapy for **Hurley I < 4 flares
/ year**

Provide prescriptions in advance

During flares
incision-drainage to relieve pain

In case of relapse at same location, limited excision

- fusiform
- Or Marsupialization

Hurley II



Suggest the same regimen as for
Hurley I ≥ 4 flares/year

In cases of failure#

Specialised multidisciplinary care**

**Wide excision of bands and sinus tracts or
marsupialisation**

Follicular form



Suggest the same regimen as for
Hurley I ≥ 4 flares/year

In case of failure : retinoids

- Isotretinoin 0.3-0.5 mg/kg
- Alitretinoin 10 to 30 mg/d
- Acitretin 0.5 mg/kg

In case of failure

- Adalimumab 160/80/40 per week****
OR
- Infliximab 5mg/kg every 6 to 8 weeks*****
Re-evaluation at 6 months

Hurley III



Specialised multidisciplinary care**

Initial treatment

- Ceftriaxone 1 g/d (if < 60 kg) to 2 g/d (if ≥ 60 kg) (IV,
IM or SC) + metronidazole (500 mg x 3/d)
OR
- Levofloxacin (500 mg 1-2x/d) + clindamycin (600 mg
x 3/d)
For 15-21 days

and/or

Surgery
Wide excision

Preventive treatment
- Cyclines (doxycycline
100 mg/d *** or
lymecycline 300 mg/d)
OR
- Cotrimoxazole* 400/80
1/d***
**Re-evaluation at 6
months**

and/or

- Adalimumab****
160/80/40 per week
OR
- Infliximab 5mg/kg
every 6-8 weeks*****
**Re-evaluation at 6
months**

HS associated with inflammatory diseases (SpA, IBD)

Preventive treatment

- Adalimumab 160/80/40 per week****
OR
- Infliximab 5mg/kg every 6 to 8 weeks*****
Re-evaluation at 6 months

#No improvement from baseline

* In case of failure, intolerance or contraindication for cyclines (risk
of serious toxidermia)

** Medical and surgical concertation meeting specifically on HS

*** Double dose if weight > 80 kg

**** Marketing authorisation (MA) but not reimbursed in France
***** no MA

SpA: Spondyloarthropathy; IBD: Inflammatory bowel disease